Search results
...Collaboration with Lantheus Holdings, Inc. for Use of Microbubbles in Combination with...
WPRI Providence· 4 days agoVTE is a condition that occurs when a blood clot forms in a deep vein, resulting...
PVD vs. DVT: Definitions, symptoms, and treatment
Medical News Today· 6 days agoPVD is a broad term referring to disorders affecting the blood vessels. DVT is a specific issue that can affect veins distant from the heart.
SonoVascular partners with Lantheus for VTE treatment
Medical Device Network via Yahoo Finance· 4 days agoThis agreement marks a significant step in the development of a new treatment approach for deep vein...
Reasons for Heightened Thrombotic Risk in RA Remain Unclear
Medscape· 7 days agoPeople with rheumatoid arthritis (RA) have a consistently higher risk for venous thromboembolism (VTE) than the general population, but the reasons for this remain unclear ...
Inari Medical Inc (NARI) Q1 2024 Earnings: Surpasses Revenue Estimates Amidst Rising Operating ...
GuruFocus.com via Yahoo Finance· 6 days agoCompany Overview Inari Medical Inc focuses on developing products for patients with Chronic Venous...
Q1 2024 Inari Medical Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 6 days agoSegment consists of four distinct patient populations outside of VTE. together comprising a $4 billion TAM in the US alone and chronic venous disease reservoir continues to ...
Most RA Patients Meet EMA's JAK Inhibitor Warning Criteria
Medscape· 4 days agoRecent regulatory warnings could mean that four in five patients with RA may not be prescribed JAK...
Handelsbanken Fonder AB Grows Stock Position in Inari Medical, Inc. (NASDAQ:NARI)
ETF DAILY NEWS· 5 days agoHandelsbanken Fonder AB raised its holdings in Inari Medical, Inc. (NASDAQ:NARI – Free Report) by 30.7% in the fourth quarter, according to the company in its most recent disclosure with the ...
Inari Medical (NASDAQ:NARI) Price Target Lowered to $55.00 at Canaccord Genuity Group
ETF DAILY NEWS· 5 days agoInari Medical (NASDAQ:NARI – Free Report) had its price target lowered by Canaccord Genuity Group from $75.00 to $55.00 in a research report released on Wednesday, Benzinga reports. Piper Sandler ...
